Jane Street
BCLI

Jane Street’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Jane Street’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,287
Closed -$77K – 10271
2021
Q4 		$77K Hold
1,287
– – ﹤0.01% 9359
2021
Q3 		$64K Sell
1,287
-86
-6% -$4.52K ﹤0.01% 9465
2021
Q2 		$78K Sell
1,373
-1,907
-58% -$102K ﹤0.01% 9367
2021
Q1 		$188K Sell
3,280
-6,320
-66% -$477K ﹤0.01% 8314
2020
Q4 		$652K Sell
9,600
-3,687
-28% -$502K ﹤0.01% 5330
2020
Q3 		$3.37M Buy
13,287
+3,554
+37% +$728K ﹤0.01% 2290
2020
Q2 		$1.64M Buy
9,733
+7,593
+355% +$819K ﹤0.01% 3338
2020
Q1 		$149K Buy
+2,140
New +$167K ﹤0.01% 4780

Other funds holding BCLI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 22.73% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $488M AUM 17.59% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Jane Street's BCLI Position: Q3 2024 in Review

Jane Street sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2024, closing a stake of 1,322 shares — an estimated $6.71K sold.

Jane Street first reported a position in BCLI in Q1 2020 and held it in 9 quarters. The position peaked at $173K in Q4 2020. 38 funds tracked by Wall St. Rank hold BCLI as of Q3 2024.

  • Jane Street reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2024 after selling out during the quarter.
  • Jane Street sold 1,322 BRAINSTORM CELL THERAPUTC shares in Q3 2024, an estimated $6.71K.
  • Jane Street first reported a position in BRAINSTORM CELL THERAPUTC in Q1 2020 and held it in 9 quarters.
  • Jane Street's BRAINSTORM CELL THERAPUTC position peaked at $173K in Q4 2020.
  • 38 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2024.

Based on Jane Street's 13F filing for Q3 2024, filed 15 Nov 2024.